Trial Profile

A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A Cancer-Specific Plectin (CSP)-Targeting Functional Antibody in Solid Tumors That Are Likely to Express CSP

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 05 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibentatug (Primary)
Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Ovarian cancer; Pancreatic ductal carcinoma
Focus First in man; Pharmacokinetics
Sponsors ZielBio

Most Recent Events

25 Jan 2024 Status changed from active, no longer recruiting to completed.
08 Aug 2023 Status changed from recruiting to active, no longer recruiting.
06 Jun 2023 Interim results (n=21; as of 31 Jan 2023) presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com